Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 21Other hematologic neoplasm 20Plasma cell 1Gastrointestinal 1Classical hematology 1

Conditions

Myeloproliferative Disorders 2Anemia, Refractory, with Excess of Blasts 2Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Cytopenia 1

Interventions

Cyclophosphamide 63fludarabine phosphate 52Busulfan 48Cyclosporine 37Antilymphocyte Serum 36Peripheral Blood Stem Cell Transplantation 35Cytarabine 29Filgrastim 28Mycophenolic Acid 27Whole-Body Irradiation 26Radiotherapy 26Melphalan 26Cord Blood Stem Cell Transplantation 24Tacrolimus 23Methotrexate 23Methylprednisolone 21fludarabine 19Etoposide 16Thiotepa 11Granulocyte Colony-Stimulating Factor 11Azacitidine 10Alemtuzumab 9Daunorubicin 8sargramostim 7Idarubicin 7Decitabine 7Biopsy 7Topotecan 6Stem Cell Transplantation 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × decitabine and cedazuridine drug combination × Classical hematology × Clear all
NCT05600894 2026-05-13

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

National Cancer Institute (NCI)

Phase 2 Active not recruiting
132 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡